Abstract
BACKGROUND: This sub-analysis of the SPECTRA (Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam [C/T] Real-world Analysis) study aimed to describe the clinical characteristics, treatment patterns, and outcomes of hospitalized pneumonia patients treated with ceftolozane/tazobactam (C/T). [Figure: see text] METHODS: SPECTRA was a multicenter observational study conducted in 7 countries. It included adult patients (age≥18yrs) who received ≥48-hours C/T treatment (n=617). Retrospective data were extracted from medical records covering a 6-month period prior to the index date, up to 30 days after the last dose of C/T or until death. Descriptive statistics were used to analyze clinical success, all-cause in-hospital mortality (ACHM), intensive care unit (ICU) admission, length of stay (LOS) in the subcategory of pneumonia (n=182). [Figure: see text] RESULTS: The median duration of C/T treatment was 11.0 days, median time from index hospitalization admission to C/T initiation was 19.0 days, and from the first microbiological sample to C/T initiation 6.0 days. All-cause in-hospital mortality was 32.4% (n=59), with a median time from the index to death of 28.0 days. The causes of death included sepsis (38.9%) and pneumonia (18.6%) and 67% (n=122) patients were admitted to the ICU during the index hospitalization. Pseudomonas aeruginosa (PSA) was the most commonly isolated pathogen (88% of patients), with MDR PsA present in 68.4% (n=80) of pneumonia patients. CONCLUSION: In hospitalized patients with pneumonia treated with C/T in a real-world setting, clinical characteristics, treatment patterns, and outcomes provide insights into the use and effectiveness of C/T. DISCLOSURES: Emre Yucel, PhD, Merck: I am a full time Merck Employee and own stocks in the retirement plan provided by Merck.|Merck: Stocks/Bonds (Public Company) David Paterson, bioMerieux: Grant/Research Support|bioMerieux: Honoraria|Merck: Advisor/Consultant|Merck: Grant/Research Support|Merck: Honoraria|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Pfizer: Honoraria|Shionogi: Grant/Research Support|Shionogi: Honoraria Florian Thalhammer, MD, MSD: Advisor/Consultant Stefan Kluge, Prof. Dr. med., Merck & Co: Advisor/Consultant|Merck & Co: Board Member Mike Allen, PhD, Merck: I am a full time Merck Employee and own stocks in the retirement plan provided by Merck.|Merck: Stocks/Bonds (Public Company) Brune Akrich, MD, Merck: I am a full time Merck Employee and own stocks in the retirement plan provided by Merck.|Merck: Stocks/Bonds (Public Company) Yanbing Zhou, PhD, Merck: I am a full time Merck Employee and own stocks in the retirement plan provided by Merck.|Merck: Stocks/Bonds (Public Company)